Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Infantile hemangioma" patented technology

Infantile hemangiomas typically develop in the first few weeks or months of life. They are more common in Caucasians, in premature children whose birth weight is less than 3 pounds (1.4 kg), in females, and in twin births. Early lesions may resemble a red scratch or patch, a white patch, or a bruise.

Percutaneous-absorption-promoting propranolol composite phospholipid transfersome, and prepartion method and application thereof

The invention provides a composite phospholipid transfersome which promotes propranolol percutaneous absorption, and a preparation method thereof. According to the invention, two phospholipid materials with different phase-change temperatures, which are dipalmitoyl phosphatidyl choline and soybean lecithin, are adopted as a composite phospholipid material. Compared with a transfersome with a single phospholipid material in prior art, the propranolol composite phospholipid transfersome prepared with the phospholipid material provided by the invention has substantially improved encapsulation efficiency, reduced leakage, improved stability in rat plasma, and substantially improved bioavailability after percutaneous administration. The propranolol composite phospholipid transfersome provided by the invention is especially suitable to be used for treating infantile hemangioma. With the transfersome, propranolol percutaneous administration can be realized, and propranolol can directly act upon a hemangioma affected part. The treatment effect is improved, toxic and side effects are reduced, and children medication compliance can be improved. Also, the invention provides a preparation method of the propranolol composite phospholipid transfersome.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Traditional Chinese medicinal composition for treating infantile hemangiomas as well as preparation and preparation method thereof

The invention discloses a traditional Chinese medicinal composition for treating infantile hemangiomas as well as a preparation and a preparation method thereof. The traditional Chinese medicinal composition comprises the following substances in parts by weight: 1-5 parts of kelp, 1-5 parts of seaweed, 1-5 parts of red-rooted salvia, 1-5 parts of red peony root, 1-5 parts of angelica, 1-5 parts ofrehmannia, 1-5 parts of radix scrophulariae and 1-5 parts of turmeric. With the kelp and the seaweed as monarch medicines, the traditional Chinese medicinal composition fundamentally activates bloodcirculation, removes blood stasis, dissolves phlegm and induces diuresis so as to fundamentally control the disease; with the red-rooted salvia and the red peony root as ministerial medicines, the ministerial medicines supplement the monarch medicines to achieve the efficacies of activating the blood circulation and removing the blood stasis, and have the efficacies of clearing away heat and toxicmaterials; with the angelica and the rehmannia as adjuvant medicines, the adjuvant medicines adjust the body immunity and improve the medicinal effect; with the radix scrophulariae and the turmeric as conductant medicines, the conductant medicines supplement the monarch medicines and the ministerial medicines; according to a formula, various medicines are combined, the monarch medicines and the ministerial medicines cooperate with one another, and the ministerial medicines and the ministerial medicines jointly achieve the supplementing effect, so that the traditional Chinese medicinal composition can effectively treat skin hemangiomas; in addition, the hemangiomas are unlikely to relapse, and the total effective rate reaches 97.5%; the traditional Chinese medicinal composition uses natural Chinese herbs as raw materials and is exact in therapeutic effect and free of toxic and side effects.
Owner:湖北喜宝药业有限公司

Application of CD93 in preparation of early warning infantile hemangioma (IH) umbilical blood assay kit and therapeutic drug

The invention discloses the application of CD93 in the preparation of an early warning infantile hemangioma (IH) umbilical blood assay kit and a therapeutic drug. A study found that the neonatal umbilical blood serum CD93 has an important role in predicting/warning IH, and is a serum marker of IH tumors. Because IH is the most common benign tumor in infants, and the neonatal umbilical blood is easy to sufficiently collect in the early stage of IH, has no trauma, and is easy to be accepted by family members, the development of using CD93 as a umbilical blood assay kit or test paper for predicting/warning protein for warning the occurrence of IH has extremely important clinical significance and social values on the early monitoring, the early detection and the early treatment of IH, minimizing the teratogenesis rate of severe IH, and reducing the rate of misdiagnosis and mistreatment. In addition, the CD93, as transmembrane protein, can promote angiogenesis of hemangioblast stem cells, has important significance in anti-angiogenesis therapeutic targets, and can be used for preparing related therapeutic drugs and preventive drugs for early treatment and prevention of IH.
Owner:江成鸿
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products